PHAT - phathompharma.com Earnings growth forecast for next year

Official company branding of phathompharma.com (PHAT)

The expected annual EPS growth rate for the coming year reflects a trend where 189.00 becomes the new value for this metric. Phathom Pharmaceuticals (PHAT) attracts leading scientists and managers through stock options and startup drive. Business profitability relies on the expansion of insurance coverage and Voquezna sales. Simultaneously, the company is implementing automated packaging and digital document management to accelerate clinical trials.

PHAT: Phathom Earnings growth forecast for next year 07/04/2022 - 11/14/2026

Phathom Pharma - analytical breakdowns and key metrics (PHAT)

- price and consensus price forecast:
Price Chart Phathom Corp|PHAT - Forecast Levels Chart
- market capitalization statistics:
Market Capitalization Phathom Corp|PHAT - Value Adjusted for Debt and Cash
- book capitalization indicators:
Book Value per Share Phathom Pharmaceuticals|PHAT - Book Capitalization|Market Cap to Net Assets Ratio phathompharma.com|PHAT - Aggregate Business Assets
- company total debt and liquidity indicators:
Total Debt to Capital Phathom Pharmaceuticals|PHAT - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity phathompharma.com|PHAT - Company Cumulative Debt|Debt to Book Capitalization Ratio Phathom Corp|PHAT - Company Long-Term Liabilities|Company Current Liabilities Phathom Pharmaceuticals|Quick Liquidity phathompharma.com
- earnings and valuation multiples information:
PHAT - Profit After Tax|Projected Future Earnings Phathom Pharmaceuticals|PHAT - Company Value to Net Income|Forward P/E Multiple phathompharma.com|PHAT - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Phathom Corp|PHAT - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Phathom Pharmaceuticals|PHAT - Net earnings per share for the last 12 months|Quarterly EPS earnings growth phathompharma.com|PHAT - Earnings growth in current year|Earnings growth forecast for next year Phathom Pharmaceuticals
- revenue and sales proceeds data:
PHAT - Company Sales|Projected Sales Volume Phathom Pharma|PHAT - Price to Sales|Forward Price-to-Revenue Multiple Phathom Pharmaceuticals, Inc.
Fundamental company analysis:PHAT, phathompharma.com
Finished products of Phathom Pharmaceuticals, Inc.

Investors must weigh the resilience of the Phathom Pharmaceuticals (PHAT) business model against the pressure of insurance pricing policies and competition within the GI segment. By analyzing the projected net income per share growth for the coming year, one can assess the consensus EPS forecast, which reflects the company's ability to monetize new drugs and achieve operational profitability despite market risks.

Analysis of competing companies

Expected earnings per share growth for next year TERN|ironwoodpharma.com (IRWD) - Consensus forecast of earnings per share growth for next year|Expected earnings per share growth for next year CURX (curanexpharma.com)|Expected earnings per share growth for next year Immuron Ltd IMRN|Net earnings per share growth forecast for next year evokepharma.com EVOK|Projected earnings per share increase next year ENTO (Entero)|RedHill Biopharma Ltd. - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year palisadebio.com PALI|JAGX: Earnings growth forecast for next year|Progenity (BIOR) - Earnings growth forecast for next year|MORF (Morphic Holding Corp) - Earnings growth forecast for next year